Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma

International Journal of Hematology

Volumn 95, Issue 6, 2012, Pages 706-710

  Tsuda, Hiroyuki ^a   Yamasaki, Hiroshi ^a   Tsuji, Takahiro ^a   Yokoo, Eri ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Alkaline phosphatase; Bone formation; Lenalidomide; Multiple myeloma; Tetany

Indexed keywords

ALKALINE PHOSPHATASE; BENCE JONES PROTEIN; BORTEZOMIB; CALCIUM; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCONATE CALCIUM; IMMUNOGLOBULIN A; LENALIDOMIDE; MAGNESIUM; MELPHALAN; PARAPROTEIN; PARATHYROID HORMONE; PREDNISOLONE; THALIDOMIDE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AGED; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSSIFICATION; OSTEOSCLEROSIS; PANCYTOPENIA; PROTEIN EXPRESSION; RADIOGRAPHY; SIDE EFFECT; TETANY; UREA NITROGEN BLOOD LEVEL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM; DEXAMETHASONE; FEMALE; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOGENESIS; THALIDOMIDE;

EID: 84865017968     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1058-1     Document Type: Article

References (12)

1. Terpos E, Dimopoulos MA. Myeloma bone disease: Pathophysiology and management. Ann Oncol. 2005;16:1223-31. (Pubitemid 41158467)
2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33. (Pubitemid 36033957)
3. Terpos E, Dimopoulos MA, Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia. 2007;21:1875-84. (Pubitemid 47299959)
4. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burn MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71-3. (Pubitemid 43899710)
5. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Migkou M, Tsionos K, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol. 2010;21:1561-2.
6. De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestis F. Constitutive down regulation of osterix in osteoblasts from myeloma patients: in vitro effect of bortezomib and lenalidomide. Leuk Res. 2010;34:243-9.
7. Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogues but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008;33:129-36.
8. Terpos E. Advances in imaging and management of myeloma bone disease. J Clin Oncol. 2011;29:1907-15.
9. Christoulas D, Dimopoulos M, Katodritou E, Kyrtsonis M, Parharidou A, Delipasi S, et al. The combination of lenalidomide and dexamethasone reduced bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation. Haematologica. 2010;95(s2):397.
10. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescia R, et al. International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010;24:1700-12.
11. Dimopoulos MA, Palumbo A, Attal M, Baksac M, Davies EF, Delforge M, European Myeloma Network, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749-60.
12. Celgene Corpotation. Revmid Full prescribing information. http://www.revmid.com/docs/Revmid-Full-PI.pdf. Accessed Feb 2012.